Summit Therapeutics is trading 4.2% lower at $16.55 amid biotech-sector pressure, with the XBI down 2.50% during the session. - No new company-specific announcement explaining the October 6 decline appeared in the search. - AstraZeneca’s $2 billion investment was completed on October 5; available news does not directly link it to today’s move. - The broad market is higher.